(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) trifluoroacetate salt

Modify Date: 2024-01-06 17:15:33

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) trifluoroacetate salt structure	Common Name	(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) trifluoroacetate salt
	CAS Number	118102-98-0	Molecular Weight	3625.2
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₆₅H₂₅₁N₄₉O₄₀S₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of (D-Trp12,Tyr34)-pTH (7-34) amide (bovine) trifluoroacetate salt

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) is a potent and competitive antagonist of parathyroid hormone (PTH), with a Ki of 69 nM in bovine renal cortical membrane. (D-Trp12,Tyr34)-pTH (7-34) amide (bovine) can be used for growth and development regulation[1][2].

Name	(D-Trp12,Tyr34)-pTH (7-34) amide (bovine)

Description	(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) is a potent and competitive antagonist of parathyroid hormone (PTH), with a Ki of 69 nM in bovine renal cortical membrane. (D-Trp12,Tyr34)-pTH (7-34) amide (bovine) can be used for growth and development regulation[1][2].
Related Catalog	Signaling Pathways >> Others >> Thyroid Hormone Receptor Research Areas >> Metabolic Disease
Target	Ki: 69 nM (PTH)[1]
In Vitro	(D-Trp12,Tyr34)-pTH (7-34) amide (0.05-10 μM) causes a concentration-dependent inhibition of PTHrP or PTH-stimulated cAMP formation in opossum kidney (OK) cells[2]. (D-Trp12,Tyr34)-pTH (7-34) amide (0.1-10 μM) attenuates inhibition of NapiT promoted by 1 nM of either PTHrP or PTH[2].
In Vivo	(D-Trp12,Tyr34)-pTH (7-34) amide (1 mg/mL once, 0.1 mg/mL for 6 h; i.v.) has no significant effect on serum calcium levels in hypercalcemic athymic nude mice bearing a human squamous cell carcinoma of the lung[3].
References	[1]. Goldma ME, et, al. A new highly potent parathyroid hormone antagonist: [D-Trp12,Tyr34]bPTH-(7-34)NH2. Endocrinology. 1988 Nov; 123(5): 2597-9. [2]. Pizurki L, et, al. Inhibition by (D-Trp12,Tyr34)bPTH(7-34)amide of PTH and PTHrP effects on Pi transport in renal cells. Am J Physiol. 1990 Aug; 259(2 Pt 2): F389-92. [3]. Kukreja SC, Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy. Endocrinology. 1994 May; 134(5): 2184-8.